Business, energy, technology, markets and global industry news from Business News Today

Alport syndrome

PharmaDeviceNews Alport syndrome
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

What will Eloxx Pharmaceuticals’ EXACT trial reveal about exaluren in Alport syndrome?

Eloxx starts Phase 2b testing of exaluren in nonsense mutation Alport syndrome, with a 16-week biomarker readout expected in mid-2027.

Read More
Pharma & Biotech

ENYO Pharma’s vonafexor reverses kidney decline in Alport syndrome with sustained benefit

Vonafexor reversed kidney decline in Alport syndrome patients. Find out what ENYO Pharma’s Phase 2 results could mean for FXR drugs and kidney care.

Read More